

Intas Biopharma eyes Gulf foray

TIMES NEWS NETWORK

Ahmedabad: Intas Biopharmaceuticals Ltd (IBPL) has firmed up plans to supply and market indigenously developed biotech products in the Gulf markets in the first quarter of fiscal 2008-09.

The company is also exploring

the possibility of tapping the contract research and contract manufacturing segment in the Gulf Cooperation Council (GCC) region, which has a combined economy of \$715 billion and comprises six countries of Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates.

Initially, the firm plans to supply and market Neukine, Erykine and Intalfa in the Gulf region and later expand operations there, company officials said. The company has already got permission from GCC's ministry of commerce for registration of a company and was now exploring various op-

tions for the Gulf foray, company officials said. IBPL chief executive (marketing) Simon Daniel said, "With surge in demand of oncology products, GCC region holds tremendous potential for Indian companies like ours, which has a dedicated biotech and oncology product pipeline."